Zyversa Therapeutics Inc
zyversa.comWhat Do They Do?
Develops drug candidates for patients with chronic kidney and inflammatory diseases.
10-K for FY2025, filed Mar 31, 2026We are a clinical stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or…View ↗
Cholesterol Efflux MediatorTM VAR 200 (2-hydroxypropyl-beta-cyclodextrin or “2HPβCD”) is an injectable drug in clinical development for…View ↗
Inflammasome ASC Inhibitor IC 100 is a humanized monoclonal antibody in preclinical development for treatment of inflammatory conditions.…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
-
Jul 16, 2026
Trading moves from OTCQB to OTC Pink
Sources
8-K, filed Jul 16, 2026
Effective July 16, 2026, ZyVersa Therapeutics, Inc. ceased trading on the OTCQB® Venture Market and commenced trading on the OTC Pink…View ↗
Loading...
